News | News By Subject | News by Disease News By Date | Search News

Attention-Deficit Hyperactivity Disorder (ADHD) News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
7 PDUFA Dates to Mark on Your Calendars for September     9/7/2017
With Baxalta (BXLT) Boosting Rare Drugs, Shire (SHPG) May Spin Off ADHD Drugs Business     8/4/2017
Investors Gain Focus as Shire (SHPG) Stock Rises at Positive ADHD Drug News     6/30/2016
FDA Indicates Deficiencies in Neos Therapeutics (NEOS)’s ADHD New Drug Application     10/20/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Mallinckrodt Pharmaceuticals (MNK)'s Generic ADHD Drug Does Not Measure Up To Johnson & Johnson (JNJ)'s Concerta: FDA     11/14/2014
FDA Needs More Pediatric Data For Resubmission Of ADHD Drug: Shire     10/9/2014
Alcobra (ADHD)'s ADHD Drug Metadoxine Meets Goals In Late-Stage Study     10/6/2014
Supernus Pharmaceuticals (SUPN) Snags FDA Fast Track Designation For ADHD Drug SPN-810     8/15/2014
Theravance, Inc. (THRX) Abandons ADHD Drug After Drug Fails Phase 2 Study     11/15/2013
FDA Approves Shire plc's Vyvanse for Children With ADHD     5/2/2013
Shire plc Settles With Actavis (ACT), Watson Pharmaceuticals, Inc. (WPI) on ADHD Drug     4/25/2013
Shire plc ADHD Drug Elvanse Close to Europe Approval     12/19/2012

News from Around the Web
Betsy DeVos Backs A Technique Claiming To Cure ADHD Without Medication—But The Science Is Questionable     4/4/2017
Unhealthy Diet During Pregnancy Could Be Linked To ADHD, University College London Study     8/19/2016
Acetaminophen During Pregnancy Could Cause ADHD, University of Bristol Study Finds     8/16/2016
Could We One Day Heal The Mind By Taking Control Of Our Dreams?     7/15/2016
Adults, Especially Women, May Develop ADHD Later In Life -- Or Else Were Missed As Kids, Published In JAMA Psychiatry     5/20/2016
Phthalates, Chemicals Used In Some Medical Devices, Could Be Creating Attention Deficit In Children, University of Antwerp Study     4/27/2016
Videogame Addiction Linked To ADHD, University Of Bergen Study     4/26/2016
Could A Brain "Growth Chart" Spot Attention Problems Early? University of Michigan Study Suggests     4/15/2016
Maternal Obesity Tied To Increase In Child Behavior Problems, University of Pittsburgh Study     3/25/2016
Childhood ADHD Doubles Obesity Risk In Women, Mayo Clinic Study Shows     2/5/2016
New Video Game Aims To Help Kids With ADHD, Akili Interactive Labs Reveals     1/25/2016
Technology Makes ADHD Better, Not Worse -- Part I     6/26/2015
How Drug Companies Benefit From Adult ADHD     6/23/2015
Common Pesticide Linked To ADHD In Boys, Cincinnati Children's Hospital Medical Center Study     6/4/2015
Workers Seeking Productivity In A Pill Are Abusing ADHD Drugs     4/23/2015

Press Releases
Shire (SHPG), Shionogi's Adult ADHD Drug Hits Phase III Goals     9/20/2017
KemPharm (KMPH) Files IND For KP484 For The Treatment Of ADHD, An Investigational Prodrug Of Methylphenidate     9/20/2017
Neos Therapeutics (NEOS) Receives U.S. FDA Approval Of Adzenys ER (Amphetamine) Extended-Release Oral Suspension For The Treatment Of ADHD In Patients 6 Years And Older     9/18/2017
Neos Therapeutics (NEOS) Announces Launch Of Cotempla XR-ODT (Methylphenidate) Extended-Release Orally Disintegrating Tablets For The Treatment Of ADHD In Patients 6 To 17 Years Old     9/5/2017
Sunovion Submits New Drug Application For Dasotraline To The FDA For The Treatment Of Patients With ADHD     8/31/2017
DURECT (DRRX) Release: ORADUR-Methylphenidate ER Capsule Achieves Primary Endpoint In Phase III Study In ADHD In Taiwan     8/8/2017
KemPharm (KMPH) Strengthens ADHD Prodrug Pipeline With Development Of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate     6/28/2017
Shire (SHPG): U.S. FDA Approves Mydayis (Mixed Salts Of A Single-Entity Amphetamine Product) - A New Once-Daily Option For ADHD Symptom Control In Patients 13 Years And Older     6/21/2017
Neos Therapeutics (NEOS) Announces FDA Approval Of Cotempla XR-ODT (Methylphenidate) Extended-Release Orally Disintegrating Tablets For The Treatment Of ADHD In Patients 6 To 17 Years Old     6/20/2017
NLS Pharma Touts Positive Phase II ADHD Data     5/31/2017
Cingulate Initiates First Human Clinical Trial     5/31/2017
NLS Pharma Announces New Information In Support Of The Mechanism Of Action Of Its Lead Compound NLS-1 Mazindol CR     5/30/2017
NLS Pharma Announces Phase ll Study Of NLS-1 (Mazindol) In Adult ADHD Patients Has Met All Primary And Secondary Endpoints     5/16/2017
Sunovion Announces Positive Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD     4/21/2017
Aevi Genomic Medicine (GNMX) To Present Updated Results From SAGA Trial Of AEVI-001 At The 6th World Congress On ADHD     4/13/2017